Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AQXP

Aquinox Pharmaceuticals (AQXP) Stock Price, News & Analysis

Aquinox Pharmaceuticals logo

About Aquinox Pharmaceuticals Stock (NASDAQ:AQXP)

Key Stats

Today's Range
$55.00
$73.59
50-Day Range
$3.68
$4.03
52-Week Range
$2.00
$3.84
Volume
962,458 shs
Average Volume
239,362 shs
Market Capitalization
$1.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive AQXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquinox Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AQXP Stock News Headlines

Mirum Pharmaceuticals, Inc. (MIRM)
Why Aquinox Pharma (AQXP) Stock Might be a Great Pick
626 winning trades out of 647…
Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trader has done over the past 8 years—closing 647 trades, with an unbelievable 97% win rate. Now, for the first time, he's breaking his silence and revealing his personal technique for success.
See More Headlines

AQXP Stock Analysis - Frequently Asked Questions

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) issued its earnings results on Thursday, November, 8th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.43.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), XOMA (XOMA), Alnylam Pharmaceuticals (ALNY) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/08/2018
Today
11/04/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AQXP
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-31,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$25 million
Book Value
$3.09 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.55 billion
Optionable
Not Optionable
Beta
-7.37
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:AQXP) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners